Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > BUSINESS
BUSINESS
- Astellas Secures Q1 Growth as Xtandi, Betanis Offset LOE Impact
July 31, 2019
- Eisai Halts Epilepsy Drug Studies after Death in Japan PI
July 31, 2019
- Pfizer Japan Seeks to Expand Bosulif Label into 1st-Line CML
July 31, 2019
- Otsuka Ups Half-Year Outlook on Bullish Jynarque
July 31, 2019
- Xtandi Filed for Hormone-Sensitive Prostate Cancer in Japan
July 31, 2019
- Over 1,000 GSK Staffers Worked from Home amid Govt’s Telework Campaign
July 30, 2019
- NEC Snaps Up Norway’s Bioinformatics Firm
July 30, 2019
- Sumitomo Dainippon Ekes Out Quarterly Growth as North America Sales Offset Japan Dip
July 30, 2019
- Shionogi’s Q1 Sales Sag 10.5% after Hefty Xofluza Milestone Gain
July 30, 2019
- Mitsubishi Tanabe’s Sales Fall 6.9% as Gilenya Snafu Takes Toll
July 30, 2019
- Lonsurf Gets EU Nod for Gastric Cancer: Taiho
July 30, 2019
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
- Bayer Files Eylea for Neovascular Glaucoma
July 29, 2019
- Takeda, Meiji to End Copromotion for Rozerem
July 29, 2019
- Pfizer, Takeda Wind Up Enbrel Copromotion
July 29, 2019
- Chugai Nets 40%-Plus Profit Rise, but Keeps 3-Year EPS Target; President Nixes Avastin Biosame
July 26, 2019
- Opdivo Posts Mixed Results in 1st-Line NSCLC, Scores Win in I/O-I/O Combo
July 26, 2019
- Sumitomo Dainippon to Invest in US Blood Sample Device Startup
July 26, 2019
- EMA Accepts Xtandi for Review in Hormone-Sensitive Prostate Cancer
July 25, 2019
- Novo Files Oral Semaglutide in Japan
July 25, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…